Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,466 shares of the medical equipment provider’s stock after purchasing an additional 1,545 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Intuitive Surgical were worth $2,980,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Delos Wealth Advisors LLC increased its position in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Baystate Wealth Management LLC lifted its holdings in Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC lifted its holdings in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the period. Able Wealth Management LLC bought a new position in Intuitive Surgical in the 4th quarter valued at about $28,000. Finally, MeadowBrook Investment Advisors LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $30,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 0.0 %

Shares of Intuitive Surgical stock opened at $444.70 on Thursday. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $468.78. The stock has a market capitalization of $158.02 billion, a P/E ratio of 80.25, a price-to-earnings-growth ratio of 4.77 and a beta of 1.39. The company has a 50-day simple moving average of $430.18 and a 200 day simple moving average of $400.17.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the business earned $1.18 EPS. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Activity

In other Intuitive Surgical news, Director Mark J. Rubash sold 1,709 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $380.00, for a total transaction of $649,420.00. Following the sale, the director now owns 16,051 shares of the company’s stock, valued at approximately $6,099,380. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Gary S. Guthart 7,440 shares of the business’s stock in a transaction dated Tuesday, July 30th. The was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark J. Rubash sold 1,709 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total transaction of $649,420.00. Following the sale, the director now directly owns 16,051 shares of the company’s stock, valued at $6,099,380. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,771 shares of company stock worth $6,239,210. 0.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Citigroup raised their price objective on shares of Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Piper Sandler boosted their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Robert W. Baird upped their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Finally, Evercore ISI dropped their target price on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $438.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.